After bringing groundbreaking treatment advancements to oncology, CAR T therapies are beginning to show promise in additional therapeutic areas. As these advanced therapies enter clinical trials in new patient communities, successful programs rely on understanding which elements of the oncology construct can be seamlessly applied in new settings.
In this recorded webinar, panelists discuss how collaboration between therapeutically aligned teams impacts study delivery for CAR T in autoimmune disease and neurology clinics. Topics include considerations for sponsor, site, and patient stakeholders.
Watch now on-demand.
Authors:
Nathan Chadwick
Senior Director, Therapeutic Strategy Lead, Rare Disease
Amy Raymond, PhD, PMP
Executive Director, Therapeutic Strategy Lead, Rare Disease & Cellular and Genetic Medicines
Simran Padam
Medical Director, Medical Affairs
